Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Zheng S, Asnani M, Thomas-Tikhonenko A.

Cancer J. 2019 May/Jun;25(3):217-222. doi: 10.1097/PPO.0000000000000381.

PMID:
31135529
2.

Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein P, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A.

Leukemia. 2019 Mar 26. doi: 10.1038/s41375-019-0454-4. [Epub ahead of print]

PMID:
30914792
3.

Aberrant splicing in B-cell acute lymphoblastic leukemia.

Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A.

Nucleic Acids Res. 2019 Jan 25;47(2):1043. doi: 10.1093/nar/gky1231. No abstract available.

4.

Exons of Leukemia Suppressor Genes: Creative Assembly Required.

Asnani M, Thomas-Tikhonenko A.

Trends Cancer. 2018 Dec;4(12):796-798. doi: 10.1016/j.trecan.2018.10.005. Epub 2018 Oct 28. Review.

PMID:
30470300
5.

Aberrant splicing in B-cell acute lymphoblastic leukemia.

Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A.

Nucleic Acids Res. 2018 Nov 30;46(21):11357-11369. doi: 10.1093/nar/gky946. Erratum in: Nucleic Acids Res. 2019 Jan 25;47(2):1043.

6.

CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum.

Bagashev A, Sotillo E, Tang CH, Black KL, Perazzelli J, Seeholzer SH, Argon Y, Barrett DM, Grupp SA, Hu CC, Thomas-Tikhonenko A.

Mol Cell Biol. 2018 Oct 15;38(21). pii: e00383-18. doi: 10.1128/MCB.00383-18. Print 2018 Nov 1.

7.

Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.

Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, Rheingold SR, Pillai V.

Am J Hematol. 2018 Nov;93(11):E352-E355. doi: 10.1002/ajh.25235. Epub 2018 Sep 9. No abstract available.

PMID:
30058145
8.

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, Rheingold SR, Grupp SA, Thomas-Tikhonenko A, Pillai V.

Am J Hematol. 2017 Jan;92(1):E11-E13. doi: 10.1002/ajh.24594. Epub 2016 Nov 21. No abstract available.

9.

miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.

Robaina MC, Faccion RS, Mazzoccoli L, Rezende LM, Queiroga E, Bacchi CE, Thomas-Tikhonenko A, Klumb CE.

Ann Hematol. 2016 May;95(6):881-91. doi: 10.1007/s00277-016-2653-7. Epub 2016 Apr 5.

PMID:
27044389
10.

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.

Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.

11.

MYC and the art of microRNA maintenance.

Psathas JN, Thomas-Tikhonenko A.

Cold Spring Harb Perspect Med. 2014 Apr 15;4(8). pii: a014175. doi: 10.1101/cshperspect.a014175. Review.

12.

Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression.

Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A.

J Natl Cancer Inst. 2014 Apr;106(4):dju043. doi: 10.1093/jnci/dju043. Epub 2014 Mar 13.

13.

The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.

Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A.

Blood. 2013 Dec 19;122(26):4220-9. doi: 10.1182/blood-2012-12-473090. Epub 2013 Oct 29.

14.

Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma.

Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A.

RNA. 2013 Feb;19(2):177-90. doi: 10.1261/rna.036467.112. Epub 2012 Dec 18.

15.

ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C.

J Clin Invest. 2012 Dec;122(12):4621-34. doi: 10.1172/JCI62973. Epub 2012 Nov 12.

16.

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A.

J Clin Invest. 2012 Jun;122(6):2257-66. doi: 10.1172/JCI45851. Epub 2012 May 1.

17.

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A.

Cancer Res. 2011 Dec 15;71(24):7490-501. doi: 10.1158/0008-5472.CAN-11-1124. Epub 2011 Oct 25.

18.

Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC.

Zhang XY, Pfeiffer HK, Mellert HS, Stanek TJ, Sussman RT, Kumari A, Yu D, Rigoutsos I, Thomas-Tikhonenko A, Seidel HE, Chodosh LA, Packham G, Baserga R, McMahon SB.

Mol Cell Biol. 2011 Dec;31(24):5037-45. doi: 10.1128/MCB.06297-11. Epub 2011 Oct 10.

19.

The long reach of noncoding RNAs.

Sotillo E, Thomas-Tikhonenko A.

Nat Genet. 2011 Jun 28;43(7):616-7. doi: 10.1038/ng.870. No abstract available.

20.

Shielding the messenger (RNA): microRNA-based anticancer therapies.

Sotillo E, Thomas-Tikhonenko A.

Pharmacol Ther. 2011 Jul;131(1):18-32. doi: 10.1016/j.pharmthera.2011.04.006. Epub 2011 Apr 14. Review.

21.

Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.

Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, Thomas-Tikhonenko A.

Oncogene. 2011 Jun 2;30(22):2587-94. doi: 10.1038/onc.2010.634. Epub 2011 Feb 7.

22.

The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.

Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, Axelson H, Speleman F, Vandesompele J.

Mol Cell. 2010 Dec 10;40(5):762-73. doi: 10.1016/j.molcel.2010.11.038.

23.

The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.

Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A.

Cancer Res. 2010 Oct 15;70(20):8233-46. doi: 10.1158/0008-5472.CAN-10-2412. Epub 2010 Oct 12.

24.

Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.

Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A.

Adv Cancer Res. 2009;105:115-32. doi: 10.1016/S0065-230X(09)05007-6. Review.

25.

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.

J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063. Epub 2009 Apr 28.

26.

Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation.

Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, Thomas-Tikhonenko A, Mendell JT.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3384-9. doi: 10.1073/pnas.0808300106. Epub 2009 Feb 11.

27.

c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster.

Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC, Schelter JM, Cleary MA, Mendell JT, Thomas-Tikhonenko A.

Cancer Biol Ther. 2008 Nov;7(11):1758-64. Epub 2008 Nov 4.

28.

PAX5 and B-cell neoplasms: transformation through presentation.

Thomas-Tikhonenko A, Cozma D.

Future Oncol. 2008 Feb;4(1):5-9. doi: 10.2217/14796694.4.1.5. Review. No abstract available.

29.

Widespread microRNA repression by Myc contributes to tumorigenesis.

Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT.

Nat Genet. 2008 Jan;40(1):43-50. Epub 2007 Dec 9.

30.

Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells.

Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, Ahmad N, Spiegelman VS.

Cancer Res. 2007 Nov 15;67(22):10642-6.

31.

Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Kumar KG, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY.

Cancer Biol Ther. 2007 Sep;6(9):1437-41. Epub 2007 Jun 13.

32.

B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, Metzgar MH, Paterson J, Erikson J, Marafioti T, Monroe JG, Atchison ML, Thomas-Tikhonenko A.

J Clin Invest. 2007 Sep;117(9):2602-10.

33.

Aiding and ABT'ing Treatment for Glioblastoma.

Chung EY, Dews M, Maity A, Thomas-Tikhonenko A.

Cancer Biol Ther. 2007 May;6(5):802-4. Epub 2007 May 15. No abstract available.

34.

p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Yu D, Carroll M, Thomas-Tikhonenko A.

Blood. 2007 Jun 1;109(11):4936-43. Epub 2007 Feb 6.

35.

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.

Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB.

J Clin Invest. 2007 Feb;117(2):326-36. Epub 2007 Jan 18.

36.

B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.

Hodawadekar S, Yu D, Cozma D, Freedman B, Sunyer O, Atchison ML, Thomas-Tikhonenko A.

Exp Cell Res. 2007 Jan 15;313(2):331-40. Epub 2006 Oct 25.

37.
38.

Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.

Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY.

Oncogene. 2007 Mar 22;26(13):1954-8. Epub 2006 Sep 25.

39.

Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.

Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A.

Nat Genet. 2006 Sep;38(9):1060-5. Epub 2006 Jul 30.

40.

Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemia.

Cozma D, Thomas-Tikhonenko A.

Cancer Biol Ther. 2006 Jun;5(6):579-81. Epub 2006 Jun 2.

PMID:
16760643
41.

Infection & neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancer.

Bertout J, Thomas-Tikhonenko A.

Cancer Treat Res. 2006;130:167-97. Review.

PMID:
16610708
42.

Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.

O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, Dang CV.

Mol Cell Biol. 2006 Mar;26(6):2373-86.

43.
44.

Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein.

Zhang XY, DeSalle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, McMahon SB.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13968-73. Epub 2005 Sep 19.

45.
46.

Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.

Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY.

Cancer Res. 2005 Mar 1;65(5):1904-8.

47.

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS.

Mol Cell Biol. 2004 Oct;24(19):8541-55.

48.

B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5.

Johnson K, Pflugh DL, Yu D, Hesslein DG, Lin KI, Bothwell AL, Thomas-Tikhonenko A, Schatz DG, Calame K.

Nat Immunol. 2004 Aug;5(8):853-61. Epub 2004 Jul 18.

49.

Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo.

Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE.

Cancer Res. 2004 May 1;64(9):3126-36.

50.

Whence thrombospondin?

Thomas-Tikhonenko A, Iruela-Arispe ML.

Cancer Biol Ther. 2004 Apr;3(4):406-7. Epub 2004 Apr 29. No abstract available.

PMID:
15107618

Supplemental Content

Loading ...
Support Center